期刊
CURRENT OPINION IN CARDIOLOGY
卷 26, 期 6, 页码 569-575出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/HCO.0b013e32834b7f95
关键词
atherosclerosis; endothelial cells; microRNA; monocytes; smooth muscle cells
资金
- Science Foundation Ireland, Dublin, Ireland [R11482, RFP06-NMC]
- Health Research Board, Dublin, Ireland [R11831-NMC]
- Molecular Medicine Ireland, Dublin, Ireland [R12699-JOS]
Purpose of review Atherosclerotic lesion vulnerability leading to plaque rupture is a major cause of morbidity in western society. Although several recent major trials have identified statins and angiotensin-converting enzyme inhibitors as having a pleiotropic benefit, no current therapeutic regime directly targets atherosclerosis. The emerging functions of microRNAs (miRs) in regulating gene expression have opened diverse possibilities in understanding plaque biology and in offering new therapeutic strategies. In this review, we consider vascular endothelial cells, smooth muscle cells and monocytes as the main cellular participants in vessel homeostasis during atherosclerosis evolution and discuss how they are functionally modified by miRs and how these modifications may allow therapeutic targeting. Recent findings Emerging roles for miRs in the pro-inflammatory functions of monocytes and macrophages, and proangiogenic functions of endothelial cells, suggest that miRs regulating these processes are potential targets. Conversely, the contribution of smooth muscle cells to plaque integrity may be augmented by miR-based agents. Recent investigations have uncovered key roles for miRs in each of these areas, which may be targeted through either silencing of proatherogenic or augmentation of antiatherogenic pathways. Summary With emerging miR-based therapeutics, a new paradigm for therapeutic intervention with the ultimate goal of plaque stabilization may exist.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据